Melanotan II research guide
Cyclic synthetic melanocortin receptor agonist
A safety-led guide to Melanotan II identity, small early human studies and the TGA's 2026 findings on unapproved, inconsistently dosed products.
AUS Peptide Supply editorial team01 · Identity
What the name identifies
Melanotan II is a cyclic synthetic analogue related to alpha-melanocyte-stimulating hormone. It is distinct from afamelanotide (sometimes called Melanotan I) and from bremelanotide/PT-141. Similar informal names make exact sequence and identity confirmation essential.
02 · Evidence position
What the literature can support
The early human literature involved very small experimental studies. In Australia, the TGA states that Melanotan II is prescription-only, is not approved as a tanning agent, and has no ARTG-listed product for supply. In 2026 the regulator reported large content variation across seized nasal-spray bottles labelled as the same strength.
03 · Study-level map
Evidence and its limits
How large was the initial human evidence?
A pilot phase I study exposed three volunteers to Melanotan II under a controlled research protocol.
Limit: Three participants cannot establish population safety or justify consumer use, and the study material cannot validate online products.
What did Australian testing find?
The TGA reported that five seized products with the same labelled presentation contained materially inconsistent estimated amounts of Melanotan II.
Limit: The finding concerns the tested products, but it demonstrates why label claims cannot substitute for independent batch testing.
04 · Analytical context
Questions a batch record should answer
- 01Does the identity result distinguish Melanotan II from Melanotan I and bremelanotide?
- 02Is quantitative content measured, not just presence or chromatographic purity?
- 03For any solution, are concentration, container volume and microbiological quality independently verified?
05 · Boundary conditions
What this record does not establish
- Small historical trials do not establish safety for unapproved consumer products.
- Labelled strength may differ materially from measured content.
- This dossier does not promote tanning or human administration.
Sources checked
- 1.Evaluation of Melanotan-II in a pilot phase-I clinical study
PubMed / Life Sciences · 1996 · Primary study
- 2.Melanotan II tanning peptide products found to be inconsistently dosed
Therapeutic Goods Administration · 2026 · Regulator